Chimeric antigen receptor T-cell therapy in adult patients with B-cell lymphoproliferative diseases

Introduction. The introduction of chimeric antigen receptor (CAR) T-cell therapy is a promising treatment of patients with relapsed or refractory (R/R) B-cell lymphoproliferative diseases (LPDs).

Aim — to present the results of CAR-T-cell therapy of 6 adult patients with B-cell LPDs.

Materials and methods. This is a pilot study conducted in adult patients with R/R or persistent minimal residual disease B-cell LPDs treated with CAR-T-cells. The study was approved by a local ethical committee of National Research Center for Hematology. Patients did not have alternative options for effective and safe treatment. All patients signed an informed consent. All patients were lymphodeplated with fl udarabine and cyclophosphamide for 4 days before the introduction of CAR-T-lymphocytes. Cytokine release syndrome (CRS) was prevented by tocilizumab on the day of CAR-T-cell administration. The effi cacy and safety of CAR-T-cell therapy was evaluated.

Results. From 01.01.2020 to 01.01.2022, 10 CAR-T-cell infusions were performed for 6 adult patients (age 19–68 years, median — 32 years) with B-cell LPDs: 4 — R/R B-acute lymphoblastic leukemia, 1 — R/R diffuse large B-cell lymphoma, 1 — persistence of MRD in mantle cell lymphoma. In all patients with a R/R, median — 4 (2–5) lines of chemotherapy and/ or immunotherapy were performed before CAR-T-cell therapy. CD19 CAR-T-cells received 3 patients, CD19/CD22 CAR-Tcells — 2 patients, CD19 and CD20 CAR-T-cells received 1 patient. Autologous CAR-T-cells received 4 (66 %) patients, allogeneic CAR-T-cells received 1 patient, and one patient had two CAR-T-cell administrations — 1 autologous and 1 allogeneic. The median number of CAR-T-cells was 0.5 × 10⁶ /kg (from 0.1 × 10⁶ /kg to 3 × 10⁶ /kg). In 7 (87.5 %) of the 8 cases after CAR-T-cell administration, overall response to therapy (complete or partial remission) was achieved, and complete remission was achieved in 6 (75 %) cases. Side effects were noted after 8 of 10 CAR-T-cell transfusions: CRS in 40 % (CRS 1 — 10 %, CRS 2 — 20 %, CRS 3 — 10 %), ICANS in 10 %, tumor lysis syndrome in 20 %, multi-organ dysfunction syndrome in 10 %.  There were no lethal complications due to CAR-T-cell administrations. The median follow-up period was 6 (1–16) months. Of the 6 patients, 2 (33 %) died from relapses and progression of LPD. One (17 %) patient died in complete remission from infectious complications. Three (50 %) patients are observed till now. The median time of CAR-T-cell circulation was 33 (6– 60) days.

Conclusion. CAR-T-cell therapy is a promising treatment for R/R B-cell LPDs and LPDs with persistence of MRD after cytoreductive therapy. This type of therapy requires a multidisciplinary approach.

1. Gökbuget N., Dombret H., Ribera J.M., et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractor y acute lymphoblastic leukemia. Haematologica. 2016; 101(12): 1524–33. DOI: 10.3324/haematol.2016.144311.

2. Crump M., Neelapu S.S., Farooq U., et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood. 2017; 130(16): 1800–8. DOI: 10.1182/blood-2017-03-769620.

3. Wang M., Munoz J., Goy A., et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020; 382(14): 1331–42. DOI: 10.1056/NEJMoa1914347.KTE-X19.

4. Schuster S.J., Svoboda J., Chong E.A., et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017; 377(26): 2545–54. DOI: 10.1056/NEJMOA1708566.

5. Jackson H.J., Rafi q S., Brentjens R.J. Driving CAR T-cells forward. Nat Rev ClinOncol. 2016; 13(6): 370–83. DOI: 10.1038/nrclinonc.2016.36.

6. June C.H., O’Connor R.S., Kawalekar O.U., et al. CAR T cell immunotherapy for human cancer. Science. 2018; 359(6382): 1361–5. DOI: 10.1126/science.aar6711.

7. Jensen M.C., Popplewell L., Cooper L.J., et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specifi c chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transpl. 2010; 16(9): 1245–56. DOI: 10.1016/J.BBMT.2010.03.014.

8. Kochenderfer J.N., Wilson W.H., Janik J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010; 116(20): 4099–102. DOI: 10.1182/blood-2010-04-281931.

9. Brentjens R.J., Rivière I., Park J.H., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011; 118(18): 4817–28. DOI: 10.1182/blood-2011-04-348540.

10. Porter D.L., Levine B.L., Kalos M., et al. Chimeric antigen receptor — modifi ed T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8): 725. DOI: 10.1056/NEJMoa1103849.

11. Park J.H., Rivière I., Gonen M., et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018; 378(5): 449–59. DOI: 10.1056/NEJMoa1709919.

12. Maude S.L., Laetsch T.W., Buechner J., et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5): 439–48. DOI: 10.1056/NEJMoa1709866.

13. Shah B.D., Bishop M.R., Oluwole O.O., et al. KTE-X19 anti-CD19 CAR Tcell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021; 138(1): 11–22. DOI: 10.1182/blood.2020009098.

14. Shah B.D., Ghobadi A., Oluwole O.O., et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021; 398(10299): 491–502. DOI: 10.1016/S0140-6736(21)01222-8.

15. Neelapu S.S., Locke F.L., Bartlett N.L., et al. Axicabtagene ciloleucel CAR Tcell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26): 2531–44. DOI: 10.1056/NEJMoa1707447.

16. Locke F.L., Ghobadi A., Jacobson C.A., et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019; 20(1): 31–42. DOI: 10.1016/S1470-2045(18)30864-7.

17. Schuster S.J., Bishop M.R., Tam C.S., et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380(1): 45–56. DOI: 10.1056/NEJMoa1804980.

18. Schuster S.J., Tam C.S., Borchmann P., et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22(10): 1403–15. DOI: 10.1016/S1470-2045(21)00375-2.

19. Wang M., Munoz J., Goy A., et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020; 382(14): 1331–42. DOI: 10.1056/NEJMoa1914347.

20. Neelapu S.S., Dickinson M., Ulrickson M.L., et al. Interim analysis of ZUMA12: A phase 2 study of axicabtagene ciloleucel (Axi-Cel) as fi rst-line therapy in patients (Pts) with high-risk large B cell lymphoma (LBCL). Blood. 2020; 136(Supplement 1): 49. DOI: 10.1182/blood-2020-134449.

21. Approved Cellular and Gene Therapy Products FDA. URL: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products

22. Neelapu S.S., Locke F.L., Bartlett N.L., et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26): 2531–44. DOI: 10.1056/NEJMoa1707447.

23. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993; 329(14): 987–94. DOI: 10.1056/NEJM199309303291402.

24. Wei J., Guo Y., Wang Y., et al. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. 2021; 18(4): 792–804. DOI: 10.1038/s41423-020-00555-x.

25. Lee D.W., Santomasso B.D., Locke F.L., et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019; 25(4): 625–38. DOI: 10.1016/j.bbmt.2018.12.758.

26. Shchekina A.E., Galstyan G.M., Gavrilina O.A., et al. Extracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report. Terapevticheskiy arkhiv. 2021; 93(7): 811–7. DOI: 10.26442/00403660.2021.07.200931. (In Russian).

27. Sterner R.C., Sterner R.M. CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 2021; 11(4): 69. DOI: 10.1038/s41408-021-00459-7.

28. Majzner R.G., Mackall C.L. Tumor antigen escape from CAR T-cells therapy. Cancer Discov. 2018; 8(10): 1219–26. DOI: 10.1158/2159-8290.CD-18-0442.

29. Maude S.L., Teachey D.T., Porter D.L., Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015; 125(26): 4017–23. DOI: 10.1182/blood-2014-12-580068.

30. Rafi q S., Hackett C.S., Brentjens R.J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020; 17(3): 147–67. DOI: 10.1038/s41571-019-0297-y.

31. Yang J.C., Plastaras J.P. Navigating the narrow bridge to CAR T-cell therapy. Blood Adv. 2020; 4(13): 2884–5. DOI: 10.1182/bloodadvances.2020002346.

32. Pinnix C.C., Gunther J.R., Dabaja B.S., et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 2020; 4(13): 2871–83. DOI: 10.1182/bloodadvances.2020001837.

33. Neelapu S.S. Dickinson M., Munoz J., et al. Primary analysis of ZUMA-12: A phase 2 study of axicabtagene ciloleucel (Axi-Cel) as fi rst-line therapy in patients with high-risk large B-cell lymphoma (LBCL). Blood. 2021; 138(Suppl 1): 739. DOI: 10.1182/blood-2021-148009.

34. Meignan M., Barrington S., Itti E., et al. Report on the 4th International Workshop on positron emission tomography in lymphoma held in Menton, France, 3–5 October 2012. Leuk Lymphoma. 2014; 55(1): 31–7. DOI: 10.3109/10428194.2013.802784.

35. Ruppert A.S., Dixon J.G., Salles G., et al. International prognostic indices in diffuse large B-cell lymphoma: A comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020; 135(23): 2041–8. DOI: 10.1182/blood.2019002729.

36. Sun S., Hao H., Yang G., et al. Immunotherapy with CAR-modifi ed T cells: Toxicities and overcoming strategies. J Immunol Res. 2018; 2018: 2386187. DOI: 10.1155/2018/2386187.

37. Pavlova A.A., Maschan M.A., Ponomarev V.B. Adoptive immunotherapy with genetically modifi ed T-lymphocytes expressing chimeric antigenic receptors. Onkogematologiya. 2017; 12(1): 17–32. DOI: 10.17650/1818-8346-2017-12-1-17-32. (In Russian).

38. Linette G.P., Stadtmauer E.A., Maus M.V., et al. Cardiovascular toxicity and titin cross-reactivity of affi nity-enhanced T cells in myeloma and melanoma. Blood. 2013; 122(6): 863–71. DOI: 10.1182/blood-2013-03-490565.

39. Azoulay É., Castro P., Maamar A., et al. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): An international, multicentre, observational cohort study. Lancet Haematol. 2021; 8(5): e355–64. DOI: 10.1016/S2352-3026(21)00060-0.

40. Yan Z., Zhang H., Cao J., et al. Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment. Front Immunol. 2021; 12: 611366. DOI: 10.3389/FIMMU.2021.611366.

41. Gardner R.A., Finney O., Annesley C., et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defi ned formulation and dose in children and young adults. Blood. 2017; 129(25): 3322–31. DOI: 10.1182/blood-2017-02-769208.

42. Lee D.W., Gardner R., Porter D.L., et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2): 188–95. DOI: 10.1182/blood-2014-05-552729.

43. Kochenderfer J.N., Dudley M.E., Carpenter R.O., et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013; 122(25): 4129–39. DOI: 10.1182/blood-2013-08-519413.

44. Lee D.W., Kochenderfer J.N., Stetler-Stevenson M., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet. 2015; 385(9967): 517–28. DOI: 10.1016/S0140-6736(14)61403-3.

45. Brudno J.N., Somerville R.P.T., Shi V., et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016; 34(10): 1112–21. DOI: 10.1200/JCO.2015.64.5929.

46. Locke F.L., Neelapu S.S., Bartlett N.L., et al. Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017; 25(1): 285–95. DOI: 10.1016/j.ymthe.2016.10.020.

47. Ali S.A., Shi V., Maric I., et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016; 128(13): 1688–700. DOI: 10.1182/blood-2016-04-711903.

48. Alvi R.M., Frigault M.J., Fradley M.G., et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019; 74(25): 3099–108. DOI: 10.1016/j.jacc.2019.10.038.

49. Hanidziar D., Bittner E. A growing problem of critical illness due to chimeric antigen receptor T-cell therapy. Crit Care Med. 2018; 46(11): e1086–7. DOI: 10.1097/CCM.0000000000003374.

50. Jhaveri K.D., Rosner M.H. Chimeric antigen receptor T cell therapy and the kidney: What the nephrologist needs to know. Clin J Am Soc Nephrol. 2018; 13(5): 796–8. DOI: 10.2215/CJN.12871117.

51. Gupta S., Seethapathy H., Strohbehn I.A., et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma. Am J Kidney Dis. 2020; 76(1): 63–71. DOI: 10.1053/j.ajkd.2019.10.011.

52. Gutgarts V., Jain T., Zheng J., et al. Acute kidney injury after CAR-T cell therapy: Low incidence and rapid recovery. Biol Blood Marrow Transplant. 2020; 26(6): 1071–6. DOI: 10.1016/j.bbmt.2020.02.012.

53. Wang Y., Qi K., Cheng H., et al. Coagulation disorders after chimeric antigen receptor T cell therapy: Analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transpl. 2020; 26(5): 865–75. DOI: 10.1016/j.bbmt.2019.11.027.

54. Taylor Jr F., Toh C.-H., Hoots W.K., et al. Towards defi nition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001; 86(5): 1327– 30.

55. Buechner J., Grupp S.A., Hiramatsu H., et al. Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Adv. 2021; 5(2): 593–601. DOI: 10.1182/bloodadvances.2020002757.

56. Hashmi H., Mirza A.S., Darwin A., et al. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 2020; 4(17): 4086. DOI: 10.1182/bloodadvances.2020002060.

57. Jiang H., Liu L., Guo T., et al. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Ann Hematol. 2019; 98(7): 1721–32. DOI: 10.1007/s00277-019-03685-z.

58. Hay K.A., Hanafi L.A., Li D., et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modifi ed T-cell therapy. Blood. 2017; 130(21): 2295–306. DOI: 10.1182/blood-2017-06-793141.

59. Knipe L., Meli A., Hewlett L., et al. A revised model for the secretion of tPA and cytokines from cultured endothelial cells. Blood. 2010; 116(12): 2183–91. DOI: 10.1182/blood-2010-03-276170.

60. Xiao X., Huang S., Chen S., et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021; 40(1): 367. DOI: 10.1186/s13046-021-02148-6.

61. Kotch C., Barrett D., Teachey D.T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019; 15(8): 813–22. DOI: 10.1080/1744666X.2019.1629904.

62. Martino M., Alati C., Canale F.A., et al. A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia. Int J Mol Sci. 2021; 22(4): 1–18. DOI: 10.3390/ijms22042150.

63. Zhang X., Lu X.-A., Yang J., et al. Effi cacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020; 4(10): 2325–38. DOI: 10.1182/bloodadvances.2020001466.